CN114917350A - Cftr增强剂在注意缺陷与多动障碍中的应用及产品 - Google Patents
Cftr增强剂在注意缺陷与多动障碍中的应用及产品 Download PDFInfo
- Publication number
- CN114917350A CN114917350A CN202210703167.9A CN202210703167A CN114917350A CN 114917350 A CN114917350 A CN 114917350A CN 202210703167 A CN202210703167 A CN 202210703167A CN 114917350 A CN114917350 A CN 114917350A
- Authority
- CN
- China
- Prior art keywords
- cftr
- product
- attention deficit
- ivacaftor
- hyperactivity disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000013403 hyperactivity Diseases 0.000 title claims abstract description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 20
- 230000006735 deficit Effects 0.000 title claims abstract description 18
- 239000003623 enhancer Substances 0.000 claims abstract description 30
- PURKAOJPTOLRMP-UHFFFAOYSA-N ivacaftor Chemical compound C1=C(O)C(C(C)(C)C)=CC(C(C)(C)C)=C1NC(=O)C1=CNC2=CC=CC=C2C1=O PURKAOJPTOLRMP-UHFFFAOYSA-N 0.000 claims description 31
- UFSKUSARDNFIRC-UHFFFAOYSA-N lumacaftor Chemical compound N1=C(C=2C=C(C=CC=2)C(O)=O)C(C)=CC=C1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 UFSKUSARDNFIRC-UHFFFAOYSA-N 0.000 claims description 31
- 229960004508 ivacaftor Drugs 0.000 claims description 30
- 229960000998 lumacaftor Drugs 0.000 claims description 30
- 239000012744 reinforcing agent Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000012530 fluid Substances 0.000 abstract description 2
- 230000005856 abnormality Effects 0.000 abstract 1
- 230000003542 behavioural effect Effects 0.000 abstract 1
- 229940126585 therapeutic drug Drugs 0.000 abstract 1
- 241000252212 Danio rerio Species 0.000 description 18
- 208000035475 disorder Diseases 0.000 description 13
- 241000251468 Actinopterygii Species 0.000 description 12
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 7
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 7
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 7
- 230000009182 swimming Effects 0.000 description 5
- 239000000556 agonist Substances 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 201000003883 Cystic fibrosis Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000366 juvenile effect Effects 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
Abstract
本发明公开了CFTR增强剂在注意缺陷与多动障碍中的应用及产品,属于生物工程技术领域。CFTR增强剂单独或联合使用,能够很好地恢复行为学异常表型,因此,为注意缺陷与多动障碍的新治疗药物等提供可靠的理论依据。
Description
技术领域
本发明涉及CFTR 增强剂在注意缺陷与多动障碍中的应用及产品,属于生物工程技术领域。
背景技术
注意缺陷与多动障碍 (Attention deficit and hyperactivity disorder,ADHD)俗称多动症,指发生于儿童时期,与同龄儿童相比,以明显注意集中困难、注意持续时间短暂、活动过度或冲动为主要特征的一组综合征。多动症是在儿童中较为常见的一种障碍,其患病率约为3-5%,男女比例为4:1。
目前,已发现很多方法具有减轻症状的作用,比如现有技术:CN104523932A中公开一种治疗小儿多动症的中药组合物、及其制备方法和应用,CN102416012A中公开一种治疗小儿多动症的药物组合物,CN104474341A中公开一种治疗小儿多动症的药物组合物等,但至今无法治愈ADHD,为此,需要提出更多的治疗用药物,为临床使用提供更多的参考。
发明内容
在长期的研究中,发明人团队发现:CFTR 增强剂单独或联合使用,能够很好地恢复行为学异常表型(如:活动过度、认知障碍和学习困难等异常状态),且具有统计学意义,基于此,将CFTR 增强剂应用于制备注意缺陷与多动障碍治疗的产品中,为新的治疗方案提供可靠的理论依据。
为了实现上述技术目的,提出如下的技术方案:
本技术方案提出:CFTR 增强剂在注意缺陷与多动障碍中的应用,包括所述CFTR增强剂在制备注意缺陷与多动障碍治疗的产品中的应用。
进一步的,所述CFTR 增强剂包括Ivacaftor或/和VX-809。优选的,CFTR 增强剂包括Ivacaftor和VX-809。
进一步的,所述CFTR 增强剂中,Ivacaftor终浓度为10 µm,VX-809终浓度为10 µm。
本技术方案还提出:CFTR 增强剂或其药学上可用的盐为活性成分,以及药学上可接受的载体、稀释剂和赋形剂组成的药物组合物的产品。
进一步的,所述产品为用于治疗注意缺陷与多动障碍的药物组合物。
进一步的,所述CFTR 增强剂包括Ivacaftor或/和VX-809。优选的,CFTR 增强剂包括Ivacaftor和VX-809。
进一步的,所述CFTR 增强剂中,Ivacaftor终浓度为10 µm,VX-809终浓度为10 µm。
在本技术方案中,涉及的术语包括:
CFTR,囊性纤维化跨膜调节因子(cystic fibrosis transmembrane conductanceregulator);
Ivacaftor (VX-770)为一种CFTR的选择性增强剂,靶向作用于G551D-CFTR和F508del-CFTR,提高G551D、 F508del和野生型CFTR 的离子通道开放概率;
VX-809 (Lumacaftor) 通过促进突变型CFTR(F508del-CFTR)的成熟,从而纠正囊性纤维症中常见的CFTR突变,提高CFTR成熟度,且增强CFTR的氯离子运输能力。
采用本技术方案,带来的有益技术效果为:
一、本发明首次将CFTR 增强剂单独或联合使用,应用于制备注意缺陷与多动障碍治疗的产品中。该CFTR 增强剂可显著的恢复行为学异常表型,为注意缺陷与多动障碍的新治疗方案提供可靠的理论依据;
其中,较发明人前期研究“CN109663129A扩张型心肌病治疗药物及其应用”而言,本发明为CFTR 增强剂的一种全新用途;
二、本发明通过建立ADHD斑马鱼模型,证据充分,具有很强的理论支撑,能够很好地表现注意缺陷与多动障碍的症状和治疗效果。其中,涉及的实验手段为本领域的成熟技术,易操作,表现性强。且选用了特定的CFTR 增强剂,对注意缺陷与多动障碍的治疗具有明显效果,便于进行推广使用;
三、将CFTR 增强剂Ivacaftor与VX-809一并应用于制备注意缺陷与多动障碍治疗的产品中时,即联合使用,具有更好的效果。
附图说明
图1为CFTR激动剂可显著降低ADHD斑马鱼模型的幼鱼的游动距离的结果图;
图2为CFTR激动剂可显著降低ADHD斑马鱼模型的幼鱼的游动速度的结果图;
图3为CFTR激动剂可显著降低ADHD斑马鱼模型的成鱼的镜面攻击次数的结果图;
图4为CFTR激动剂可显著减少ADHD斑马鱼模型的成鱼提高其学习能力的学习时间的结果图。
具体实施方式
以下通过具体实施方式的描述对本发明作进一步说明,但这并非是对本发明的限制,本领域技术人员根据本发明的基本思想,可以做出各种修改或改进,但是只要不脱离本发明的基本思想,均在本发明的范围之内。
在如下实施例中,涉及的ADHD斑马鱼模型,来自苏州大学,通过per1b基因突变而构建,详见“Circadian Modulation of Dopamine Levels and Dopaminergic NeuronDevelopment Contributes to Attention Deficiency and Hyperactive Behavior,DOI:10.1523/JNEUROSCI.2551-14.2015”。
实施例1
本实施例提出:CFTR 增强剂在注意缺陷与多动障碍中的应用,包括CFTR 增强剂在制备注意缺陷与多动障碍治疗的产品中的应用。其中,CFTR 增强剂包括Ivacaftor或/和VX-809。
作为优选,CFTR 增强剂包括Ivacaftor和VX-809,Ivacaftor终浓度为10 µm,VX-809终浓度为10 µm。
实施例2
本实施例提出:CFTR 增强剂或其药学上可用的盐为活性成分,以及药学上可接受的载体、稀释剂和赋形剂组成的药物组合物的产品。其中,产品为用于治疗注意缺陷与多动障碍的药物组合物。CFTR 增强剂包括Ivacaftor或/和VX-809。
作为优选,CFTR 增强剂包括Ivacaftor和VX-809,Ivacaftor终浓度为10 µm,VX-809终浓度为10 µm。
实施例3
基于实施例1-2,本实施例提出:基于ADHD斑马鱼模型,讨论将CFTR 增强剂(Ivacaftor与VX-809联合使用)用于ADHD斑马鱼模型的幼鱼,具体如下:
1、向ADHD斑马鱼模型的受精卵的胚胎培养基中,加入Ivacaftor和VX-809 (VX-770和VX-809皆来源于Selleck公司,目录号分别为S1144和S1565),设为实验组。其中,Ivacaftor和VX-809终浓度均为10 µm,连续处理培养5天;
2、以野生型斑马鱼、ADHD斑马鱼模型分别为对照组,相同条件下进行胚胎培养。其中,均不加入Ivacaftor和VX-809,连续处理培养5天;
3、在培养第6天,检测实验组、两个对照组对应幼鱼的游动距离和游动速度;
结果表明:联合使用Ivacaftor和VX-809,可显著降低ADHD斑马鱼模型的幼鱼的游动距离和游动速度(如图1-2所示)。
实施例4
基于实施例1-2,本实施例提出:基于ADHD斑马鱼模型,讨论将CFTR 增强剂(Ivacaftor与VX-809联合使用)用于ADHD斑马鱼模型的成鱼,具体如下:
1、向ADHD斑马鱼模型的成鱼(6个月)腹腔联合注射Ivacaftor和VX-809(VX-770和VX-809皆来源于Selleck公司,目录号分别为S1144和S1565),设为实验组。其中,注射方法参考atg7-Based Autophagy Activation Reverses Doxorubicin-InducedCardiotoxicity,DOI: 10.1161/CIRCRESAHA.121.319104,Ivacaftor及VX-809的注射量皆为2mg/kg;
2、以野生型斑马鱼、ADHD斑马鱼模型分别为对照组。其中,均不注射Ivacaftor和VX-809;
3、实验组注射1天后,检测成鱼的学习能力;同时,检测两个对照组对应成鱼的学习能力;
结果表明:联合注射Ivacaftor和VX-809,可显著降低ADHD斑马鱼模型的成鱼的镜面攻击次数,并减少其学习的时间提高其学习能力(如图3-4所示)。
Claims (6)
1.CFTR 增强剂在制备注意缺陷与多动障碍治疗的产品中的应用。
2.根据权利要求1所述的CFTR 增强剂在制备注意缺陷与多动障碍治疗的产品中的应用,其特征在于:所述CFTR 增强剂包括Ivacaftor或/和VX-809。
3.根据权利要求2所述的CFTR 增强剂在制备注意缺陷与多动障碍治疗的产品中的应用,其特征在于:所述CFTR 增强剂中,Ivacaftor终浓度为10 µm,VX-809终浓度为10 µm。
4.CFTR 增强剂或其药学上可用的盐为活性成分,以及药学上可接受的载体、稀释剂和赋形剂组成的药物组合物的产品,其中,所述产品为用于治疗注意缺陷与多动障碍的药物组合物。
5.根据权利要求4所述的产品,其特征在于:所述CFTR 增强剂包括Ivacaftor或/和VX-809。
6.根据权利要求5所述的产品,其特征在于:所述CFTR 增强剂中,Ivacaftor终浓度为10 µm,VX-809终浓度为10 µm。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210703167.9A CN114917350B (zh) | 2022-06-21 | 2022-06-21 | Cftr增强剂在注意缺陷与多动障碍中的应用及产品 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210703167.9A CN114917350B (zh) | 2022-06-21 | 2022-06-21 | Cftr增强剂在注意缺陷与多动障碍中的应用及产品 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114917350A true CN114917350A (zh) | 2022-08-19 |
CN114917350B CN114917350B (zh) | 2023-06-13 |
Family
ID=82814798
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210703167.9A Active CN114917350B (zh) | 2022-06-21 | 2022-06-21 | Cftr增强剂在注意缺陷与多动障碍中的应用及产品 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114917350B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117771376A (zh) * | 2024-02-26 | 2024-03-29 | 四川大学华西第二医院 | 一类化合物在注意缺陷与多动障碍中的应用及产品 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130203814A1 (en) * | 2010-08-24 | 2013-08-08 | The Children's Hospital Of Philadelphia | Association of Rare Recurrent Genetic Variations to Attention-Deficit, Hyperactivity Disorder (ADHD) and Methods of Use Thereof for the Diagnosis and Treatment of the Same |
US20140109899A1 (en) * | 2011-06-07 | 2014-04-24 | Parion Sciences, Inc. | Aerosol delivery systems, compositions and methods |
CN104736144A (zh) * | 2012-07-27 | 2015-06-24 | A·M·G·邦特 | 外排抑制剂组合物和使用此组合物治疗的方法 |
CN106999480A (zh) * | 2014-12-03 | 2017-08-01 | H.隆德贝克有限公司 | 用于治疗adhd和帕金森氏病的低剂量a2a拮抗剂 |
CN114401948A (zh) * | 2019-09-13 | 2022-04-26 | 红牛有限公司 | 用于改善认知功能和对抗物质成瘾的噻唑和二苯基取代的亚砜 |
-
2022
- 2022-06-21 CN CN202210703167.9A patent/CN114917350B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130203814A1 (en) * | 2010-08-24 | 2013-08-08 | The Children's Hospital Of Philadelphia | Association of Rare Recurrent Genetic Variations to Attention-Deficit, Hyperactivity Disorder (ADHD) and Methods of Use Thereof for the Diagnosis and Treatment of the Same |
US20140109899A1 (en) * | 2011-06-07 | 2014-04-24 | Parion Sciences, Inc. | Aerosol delivery systems, compositions and methods |
CN104736144A (zh) * | 2012-07-27 | 2015-06-24 | A·M·G·邦特 | 外排抑制剂组合物和使用此组合物治疗的方法 |
CN106999480A (zh) * | 2014-12-03 | 2017-08-01 | H.隆德贝克有限公司 | 用于治疗adhd和帕金森氏病的低剂量a2a拮抗剂 |
CN114401948A (zh) * | 2019-09-13 | 2022-04-26 | 红牛有限公司 | 用于改善认知功能和对抗物质成瘾的噻唑和二苯基取代的亚砜 |
Non-Patent Citations (4)
Title |
---|
ANNA M. GEORGIOPOULOS ET AL.: "Screening for ADHD in adults with cystic fibrosis: Prevalence, health-related quality of life, and adherence", JOURNAL OJOURNAL OF CYSTIC FIBROSISF CYSTIC FIBROSIS * |
EVELYNE BAROUD MD ET AL.: "Management of neuropsychiatric symptoms in adults treated with elexacaftor/tezacaftor/ivacaftor", PEDIATRIC PULMONOLOGY * |
MALENA COHEN-CYMBERKNOH ET AL.: "The association between Attention-Deficit-Hyperactivity-Disorder (ADHD) symptoms and disease severity in people with Cystic Fibrosis (pwCF)", JOURNAL OF CYSTIC FIBROSIS * |
RABASSEDA X;DULSAT C;NAVARRO E;CRUCES E;GRAUL A I;JAGO C;TRACY M;史志祥;张宇辉;陈菁;: "2012年全球新药研发报告――第二部分:攻克制药/生物技术行业难关(续Ⅳ)", 药学进展, no. 12 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117771376A (zh) * | 2024-02-26 | 2024-03-29 | 四川大学华西第二医院 | 一类化合物在注意缺陷与多动障碍中的应用及产品 |
CN117771376B (zh) * | 2024-02-26 | 2024-05-03 | 四川大学华西第二医院 | 一类化合物在注意缺陷与多动障碍中的应用及产品 |
Also Published As
Publication number | Publication date |
---|---|
CN114917350B (zh) | 2023-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101228993B1 (ko) | 발효 및 배양 방법, 식물발효 엑기스, 식물발효 엑기스분말 및 이 식물발효 엑기스 배합물 | |
CN103974712A (zh) | 治疗阿尔茨海默氏症、亨廷顿氏症、孤独症和其他障碍的方法 | |
CN114917350A (zh) | Cftr增强剂在注意缺陷与多动障碍中的应用及产品 | |
Healy et al. | Bovine citrullinaemia: a clinical, pathological, biochemical and genetic study | |
CN115505551B (zh) | 瑞士乳杆菌及其在预防或治疗肾炎中的应用 | |
WO2023035867A1 (zh) | 枸杞糖肽在制备预防和/或治疗肌萎缩侧索硬化的药物中的应用 | |
CN112263595B (zh) | 罗斯氏菌(Roseburia)在制备防治焦虑症与抑郁症药物中的应用 | |
Williams | The chemistry and biochemistry of pantothenic acid | |
CN114533765B (zh) | 短双歧杆菌ccfm1025在调节幼年神经发育中的应用 | |
Shapre et al. | Brain damage and associated behavioral deficits following the administration of L-cysteine to infant rats | |
US4223040A (en) | Lauric acid for the prevention and treatment of mycobacterial diseases | |
RU2401111C1 (ru) | Препарат для лечения сальмонеллеза у молодняка сельскохозяйственных животных | |
Durant et al. | Late logarithmic Salmonella Typhimurium HEp‐2 cell association and invasion response to short‐chain fatty acid addition | |
EP1894995B1 (de) | Irilis-biopräparation auf der basis von darin enthaltenen bacillus-bakterienstämmen bacillus subtilis und bacillus licheniformis | |
RU2425674C2 (ru) | Комплексный фармацевтический препарат | |
CH674149A5 (zh) | ||
König | ‘Pink eye’or ‘zere oogjes’ or Keratoconjunctivitis Infectiosa Ovis (KIO) Clinical efficacy of a number of antimicrobial therapies | |
EP2393504B1 (de) | Ein l-ribozym enthaltende pharmazeutische zusammensetzung zur behandlung von nebenwirkungen durch gabe von spiegelmeren | |
CN110123822A (zh) | 乳源低聚糖在制备用于通过缓解肠道缺氧损伤而治疗或预防nec的药物或食品中的用途 | |
RU2804849C1 (ru) | Способ получения препарата для повышения неспецифической резистентности организма и реализации воспроизводительной продуктивности свиней | |
CN115590865B (zh) | 褐藻寡糖在制备改善肠道菌群紊乱制品中的应用 | |
RU2483566C2 (ru) | Способ повышения сохранности цыплят | |
KR102527378B1 (ko) | 2'-fl을 함유하는 도파민 감소로 말미암아 발생하는 질환의 개선, 예방 또는 치료용 조성물 | |
CN110025624B (zh) | 萘醌苷类化合物在老年痴呆中的应用及其药物制备 | |
CN115120706B (zh) | Netrin-3在制备预防和治疗神经病理性疼痛的产品中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240412 Address after: 400021 Building 2-19-6, No. 32 Guohui Road, Shimahe Street, Jiangbei District, Chongqing Patentee after: Chongqing Saikemaide Biotechnology Co.,Ltd. Country or region after: China Address before: 402260 No. 74, Linjiang Road, Yuzhong District, Chongqing Patentee before: THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL University Country or region before: China |